FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385331785> ?p ?o ?g. }

• W4385331785 endingPage "279" @default.
• W4385331785 startingPage "271" @default.
• W4385331785 abstract "BACKGROUND: Pagibaximab, a human chimeric monoclonal antibody developed against lipoteichoic acid, was effective against staphylococci preclinically and seemed safe and well tolerated in phase 1 studies. OBJECTIVE: To evaluate the clinical activity, pharmacokinetics, safety, and tolerability of weekly pagibaximab versus placebo infusions in very low birth weight neonates. PATIENTS AND METHODS: A phase 2, randomized, double-blind, placebo-controlled study was conducted at 10 NICUs. Patients with a birth weight of 700 to 1300 g and 2 to 5 days old were randomly assigned to receive 3 once-a-week pagibaximab (90 or 60 mg/kg) or placebo infusions. Blood was collected for pharmacokinetics, bacterial killing, and safety analyses. Adverse event and clinical outcome data were collected. RESULTS: Eighty-eight patients received pagibaximab at 90 (n = 22) or 60 (n = 20) mg/kg or placebo (n = 46). Groups were not different in demography, mortality, or morbidity. Pagibaximab demonstrated linear pharmacokinetics, a 14.5-day half-life, and nonimmunogenicity. Definite staphylococcal sepsis occurred in 0%, 20%, and 13% (P &lt; .11) and nonstaphylococcal sepsis occurred in 0%, 10%, and 15% (P &lt; .15) of patients in the 90 mg/kg, 60 mg/kg, and placebo groups, respectively. In all patients with staphylococcal sepsis, estimated or observed pagibaximab levels were &lt;500 μg/mL (target level) at infection. CONCLUSIONS: Three once-a-week 90 or 60 mg/kg pagibaximab infusions, in high-risk neonates, seemed safe and well tolerated. No staphylococcal sepsis occurred in infants who received 90 mg/kg. Target levels were only consistently achieved after 2 to 3 doses. Dose optimization should enhance protection." @default.
• W4385331785 created "2023-07-29" @default.
• W4385331785 creator A5000433934 @default.
• W4385331785 creator A5001608293 @default.
• W4385331785 creator A5004355264 @default.
• W4385331785 creator A5010740129 @default.
• W4385331785 creator A5012193675 @default.
• W4385331785 creator A5015864945 @default.
• W4385331785 creator A5018615631 @default.
• W4385331785 creator A5020818251 @default.
• W4385331785 creator A5023433005 @default.
• W4385331785 creator A5040018764 @default.
• W4385331785 creator A5040081537 @default.
• W4385331785 creator A5054415965 @default.
• W4385331785 creator A5058606727 @default.
• W4385331785 creator A5071974491 @default.
• W4385331785 creator A5074903948 @default.
• W4385331785 creator A5075818401 @default.
• W4385331785 creator A5086531383 @default.
• W4385331785 date "2011-08-01" @default.
• W4385331785 modified "2023-10-18" @default.
• W4385331785 title "A Randomized Study of a Monoclonal Antibody (Pagibaximab) to Prevent Staphylococcal Sepsis" @default.
• W4385331785 cites W184447267 @default.
• W4385331785 cites W1955146178 @default.
• W4385331785 cites W1968673731 @default.
• W4385331785 cites W1985452681 @default.
• W4385331785 cites W1995204654 @default.
• W4385331785 cites W2003200123 @default.
• W4385331785 cites W2005518049 @default.
• W4385331785 cites W2009567079 @default.
• W4385331785 cites W2017046795 @default.
• W4385331785 cites W2026746053 @default.
• W4385331785 cites W2062369978 @default.
• W4385331785 cites W2064482552 @default.
• W4385331785 cites W2065283067 @default.
• W4385331785 cites W2075917748 @default.
• W4385331785 cites W2078004260 @default.
• W4385331785 cites W2084584261 @default.
• W4385331785 cites W2086542713 @default.
• W4385331785 cites W2097567009 @default.
• W4385331785 cites W2101834325 @default.
• W4385331785 cites W2119910833 @default.
• W4385331785 cites W2130534359 @default.
• W4385331785 cites W2140076442 @default.
• W4385331785 cites W2155903339 @default.
• W4385331785 cites W2161551296 @default.
• W4385331785 cites W2164493556 @default.
• W4385331785 cites W2169322130 @default.
• W4385331785 cites W2329427515 @default.
• W4385331785 cites W2335360346 @default.
• W4385331785 cites W24816387 @default.
• W4385331785 doi "https://doi.org/10.1542/peds.2010-3081" @default.
• W4385331785 hasPublicationYear "2011" @default.
• W4385331785 type Work @default.
• W4385331785 citedByCount "33" @default.
• W4385331785 countsByYear W43853317852013 @default.
• W4385331785 countsByYear W43853317852014 @default.
• W4385331785 countsByYear W43853317852015 @default.
• W4385331785 countsByYear W43853317852016 @default.
• W4385331785 countsByYear W43853317852017 @default.
• W4385331785 countsByYear W43853317852018 @default.
• W4385331785 countsByYear W43853317852019 @default.
• W4385331785 countsByYear W43853317852020 @default.
• W4385331785 countsByYear W43853317852021 @default.
• W4385331785 countsByYear W43853317852022 @default.
• W4385331785 countsByYear W43853317852023 @default.
• W4385331785 crossrefType "journal-article" @default.
• W4385331785 hasAuthorship W4385331785A5000433934 @default.
• W4385331785 hasAuthorship W4385331785A5001608293 @default.
• W4385331785 hasAuthorship W4385331785A5004355264 @default.
• W4385331785 hasAuthorship W4385331785A5010740129 @default.
• W4385331785 hasAuthorship W4385331785A5012193675 @default.
• W4385331785 hasAuthorship W4385331785A5015864945 @default.
• W4385331785 hasAuthorship W4385331785A5018615631 @default.
• W4385331785 hasAuthorship W4385331785A5020818251 @default.
• W4385331785 hasAuthorship W4385331785A5023433005 @default.
• W4385331785 hasAuthorship W4385331785A5040018764 @default.
• W4385331785 hasAuthorship W4385331785A5040081537 @default.
• W4385331785 hasAuthorship W4385331785A5054415965 @default.
• W4385331785 hasAuthorship W4385331785A5058606727 @default.
• W4385331785 hasAuthorship W4385331785A5071974491 @default.
• W4385331785 hasAuthorship W4385331785A5074903948 @default.
• W4385331785 hasAuthorship W4385331785A5075818401 @default.
• W4385331785 hasAuthorship W4385331785A5086531383 @default.
• W4385331785 hasConcept C112705442 @default.
• W4385331785 hasConcept C126322002 @default.
• W4385331785 hasConcept C142724271 @default.
• W4385331785 hasConcept C168563851 @default.
• W4385331785 hasConcept C197934379 @default.
• W4385331785 hasConcept C204787440 @default.
• W4385331785 hasConcept C27081682 @default.
• W4385331785 hasConcept C2778375690 @default.
• W4385331785 hasConcept C2778384902 @default.
• W4385331785 hasConcept C42219234 @default.
• W4385331785 hasConcept C71924100 @default.
• W4385331785 hasConcept C90924648 @default.
• W4385331785 hasConceptScore W4385331785C112705442 @default.
• W4385331785 hasConceptScore W4385331785C126322002 @default.

• next